NCT03933761View on ClinicalTrials.gov

Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

July 29, 2019

Primary Completion Date

August 2, 2021

Study Completion Date

August 2, 2021

Conditions
Ovarian CancerCarcinosarcoma
Interventions
DRUG

Pamiparib

60 mg of pamiparib (3 capsules of 20mg) will be administered orally twice a day, once in the morning and once in the evening continuously in 28 day cycles.

Sponsors

Collaborators (1)

BeiGene
All Listed Sponsors
collaborator

BeiGene

INDUSTRY

lead

Australia New Zealand Gynaecological Oncology Group

OTHER

NCT03933761 - Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy | Biotech Hunter | Biotech Hunter